Haematological manifestations of Coronavirus infection | 60163
Journal of Hematology & Thromboembolic Diseases

Journal of Hematology & Thromboembolic Diseases
Open Access

ISSN: 2329-8790

+44 7868 792050

Haematological manifestations of Coronavirus infection

Webinar on 2nd European Congress on Hematology

January 24-25, 2022 | Webinar

Ramachandran Muthiah

Morning Star Hospital, India

Scientific Tracks Abstracts: J Hematol Thrombo Dis

Abstract :

The corona virus is a single-stranded RNA virus and the angiotensin converting enzyme 2 receptor (ACE-2), to which SARS-CoV-2 binds for entry into cells, found in brain vascular endothelium and smooth muscle and SARS-CoV-2 replicates in the cells. It causes oedema, cell necrosis, and broad gliocyte hyperplasia. The elevated expression of the cytokine, monokine induced by gamma interferon (known as MIG or CXC L9), and with infiltration of monocytes and macrophages plus T cells are consistent with viral CNS entry, triggering the infiltration of immune cells and the release of cytokines and chemokine’s, which contribute to tissue damage. A vacuities process similar to that for varicella zoster virus, in which viral replication in the cerebral arterial wall triggers local inflammation. SARS (Severe acute respiratory syndrome)-CoV-2 can cause damage to endothelial cells, activating inflammatory and thrombotic pathways. Endothelial cell infection or monocyte activation, up regulation of tissue factors, and the release of micro particles, which activate the thrombotic pathway and cause microangiopathy, endothelial infection by SARS-CoV-2 and stroke are consistent with a virus-associated microangiopathic process. Monocyte activation is postulated to contribute secondary haemophagocytic lymphohistiocytosis described in severe COVID-19. It is a rare hyper inflammatory condition characterized by a severe hypercytokinaemia with multiorgan failure. Thrombocytopenia with elevated D-dimer and C-reactive protein are the markers of severe COVID-19. Competitive blockage of angiotensin-converting enzyme 2 by the SARS-CoV-2 virus down-regulates angiotensin-converting enzyme 2 expression leading to uncontrolled blood pressure and the enhanced possibility of cerebrovascular accidents. Spike surface glycoprotein plays a crucial role in immunopathology. A unique furinlike cleavage site, on the spike protein, plays a crucial role in viral cell entry. Trans membrane protease, serine 2 (TMPRSS2) enzyme, is needed to activate the spike protein. A serine protease enzyme inhibitor blocks viral entry into the host cell. This phenomenon can be exploited for developing a treatment of COVID-19, in the future. Treatment with intravenous immunoglobulin’s lead to complete or partial recovery in the majority, immediate anticoagulation with low-molecular-weight heparin has been recommended for patients with COVID-19 to reduce the risk of thrombotic disease.

Biography :

Ramachandran Muthiah, Consultant Physician & Cardiologist, Zion hospital, Azhagiamandapam, Morning Star hospital, Marthandam, Kanyakumari District, India. Completed M.D. in General Medicine in 1996, D.M. in cardiology in 2003 under Tamil Nadu Dr. MGR Medical University, Chennai, India, He Worked as medical officer in Rural health services for 5 years and in teaching category as Assistant Professor at Madras medical college, Coimbatore medical college, Thoothukudi medical college and Kanyakumari medical college. Case Reports in Clinical Medicine (SCIRP) and Journal of Saudi Heart Association, special research on Rheumatic fever and Endomyocardial fibrosis in tropical belts, Myxomas, Infective endocarditis, apical hypertrophic cardiomyopathy, Ebstein’s anomaly, Rheumatic Taussig-Bing Heart, Costello syndrome and Tetralogy of Fallot.